IMV (NYSE:IMV) posted its earnings results on Friday. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.03), MarketWatch Earnings reports. The business had revenue of $0.12 million for the quarter, compared to analyst estimates of $0.05 million.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
IMV traded down $0.30 during midday trading on Friday, hitting $2.58. 8,241 shares of the company traded hands, compared to its average volume of 19,864. The company’s 50-day moving average is $2.74 and its 200 day moving average is $3.15. IMV has a 52 week low of $2.25 and a 52 week high of $7.07.
Several research firms have issued reports on IMV. Raymond James set a $10.00 target price on shares of IMV and gave the company an “outperform” rating in a research note on Thursday. HC Wainwright set a $11.50 target price on shares of IMV and gave the company a “buy” rating in a research note on Monday, September 30th. Wells Fargo & Co began coverage on shares of IMV in a research note on Monday, October 28th. They set a “market perform” rating on the stock. Finally, Zacks Investment Research cut shares of IMV from a “buy” rating to a “hold” rating in a research note on Saturday, October 26th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. IMV currently has a consensus rating of “Buy” and a consensus target price of $8.94.
IMV Company Profile
IMV, Inc is a clinical-stage biopharmaceutical company, which engages in the development of cancer immunotherapies and infectious disease vaccines. The firm’s patented platform, DepoVax, provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The company was founded by Warwick Kimmins and Brian Lowe on March 28, 2000 and is headquartered in Halifax, Canada.
Read More: Diversification For Individual Investors